Using hyperbaric oxygen therapy to improve symptoms of post COVID-19 condition
Improving Post COVID-19 Syndrome With Hyperbaric Oxygen Treatments (PCS-HBOT Study)
This study is testing if hyperbaric oxygen therapy can help people with long-lasting fatigue after having COVID-19 feel better.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Sunnybrook Health Sciences Centre Academic / other |
| Locations | 1 site (Toronto, Ontario) |
| Trial ID | NCT06082518 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of hyperbaric oxygen therapy (HBOT) for individuals suffering from post COVID-19 condition, particularly focusing on chronic fatigue. Participants, who have been diagnosed with post COVID-19 condition at least three months after their initial infection, will undergo treatment in a monoplace hyperbaric chamber. The study aims to evaluate the feasibility of conducting a larger trial by assessing adherence to the treatment protocol and the potential impact of HBOT on symptoms. The findings could inform future research on HBOT as a viable treatment option for post COVID-19 syndrome.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have been officially diagnosed with post COVID-19 condition and experience persistent symptoms, particularly chronic fatigue, for at least three months.
Not a fit: Patients with contraindications to hyperbaric treatments or those with pre-existing cognitive difficulties may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly alleviate chronic fatigue and improve the quality of life for patients suffering from post COVID-19 condition.
How similar studies have performed: While hyperbaric oxygen therapy has shown promise in treating other conditions, its application for post COVID-19 syndrome is still being explored and is considered a novel approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
1. Age ≥ 18 years old
2. Officially diagnosed with post COVID-19 condition by a healthcare practitioner
3. At least three months since SARS-CoV-2 infection
4. Symptoms that persist more than 12 weeks:
* Chronic fatigue (must include) along with one of the following symptoms:
* Difficulty thinking or problem solving ('brain fog')
* Stress or anxiety
Exclusion Criteria:
1. Contraindications/medically unfit to receive hyperbaric treatments at an outpatient facility (pneumothorax, in-patients, requiring infusions to maintain hemodynamics, active and unstable coronary disease)
2. Patients with cognitive difficulties and/or mental retardation before COVID diagnosis
3. History of traumatic brain injury
4. Unlikely to comply with follow-up assessments (e.g. no fixed address, plans to move out of town)
5. Known pregnancy or planning a pregnancy in women of childbearing age
Where this trial is running
Toronto, Ontario
- Sunnybrook Health Sciences Centre — Toronto, Ontario, Canada (Recruiting)
Study contacts
- Principal investigator: Fahad Alam, MD — Sunnybrook Health Sciences Centre
- Study coordinator: Fahad Alam, MD
- Email: fahad.alam@sunnybrook.ca
- Phone: 416-480-4864
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.